TFB Advisors LLC Raises Stock Position in United Therapeutics Corporation $UTHR

Key Points

• TFB Advisors LLC increased its stock position in United Therapeutics by 32.0% in the 2nd quarter, bringing its holdings to 4,021 shares valued at approximately $1,155,000.
• Wall Street analysts have varied ratings for United Therapeutics, with a current consensus rating of "Moderate Buy" and a target price of $461.62.
• Insider transactions show significant selling activity, with COO Michael Benkowitz selling 22,500 shares for over $9 million in September, contributing to a total of 329,935 shares sold by insiders in the last 90 days.

TFB Advisors LLC increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 32.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,021 shares of the biotechnology company's stock after purchasing an additional 975 shares during the period. TFB Advisors LLC's holdings in United Therapeutics were worth $1,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Chung Wu Investment Group LLC purchased a new position in United Therapeutics in the second quarter valued at $29,000. SVB Wealth LLC purchased a new position in United Therapeutics in the first quarter valued at $32,000. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group increased its holdings in United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after buying an additional 98 shares in the last quarter. Finally, WPG Advisers LLC purchased a new position in United Therapeutics in the first quarter valued at $60,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UTHR. Royal Bank Of Canada began coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an "outperform" rating and a $569.00 price objective for the company. Wells Fargo & Company began coverage on shares of United Therapeutics in a report on Monday. They issued an "underweight" rating and a $414.00 price objective for the company. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $461.62.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 329,935 shares of company stock worth $135,017,892 over the last 90 days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Stock Down 2.3%

Shares of NASDAQ UTHR opened at $422.53 on Wednesday. The company's 50-day simple moving average is $390.76 and its 200-day simple moving average is $329.82. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $459.48. The firm has a market cap of $19.06 billion, a price-to-earnings ratio of 16.49, a price-to-earnings-growth ratio of 4.72 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter last year, the business earned $5.85 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.